Abstracts tagged "juvenile idiopathic arthritis (JIA)"

Abstract Number: 198 • 2014 ACR/ARHP Annual Meeting
Implant Survival and Patient-Reported Outcomes after Total Hip Arthroplasty in Young Patients with JIA
Ishaan Swarup¹, Ella Christoph¹, Lisa A. Mandl², Susan M. Goodman² and Mark P. Figgie³, ¹Department of Orthopaedic Surgery, Hospital for Special Surgery, New York, NY, ²Rheumatology, Hospital for Special Surgery, New York, NY, ³Orthopedics, Hospital for Special Surgery, New York, NY
Background/Purpose : Juvenile Idiopathic Arthritis (JIA) is a common rheumatologic disease in children that often persists into adulthood. The hip joint is commonly involved, and…
Abstract Number: 1313 • 2014 ACR/ARHP Annual Meeting
Comorbidity Patterns in Children with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance Registry
Marc D. Natter¹, Mei-Sing Ong², Kenneth D. Mandl³, Laura Schanberg⁴, Yukiko Kimura⁵, Norman Ilowite⁶ and the CARRA Registry Investigators, ¹Intelligent Health Labs, Children's Hospital Boston, Boston, MA, ²Australian Institute of Health Innovation, University of New South Wales, Sydney, Australia, ³Intelligent Health Lab, Children's Hospital Boston, Boston, MA, ⁴Duke University, Durham, NC, ⁵Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, ⁶Rheumatology, Children's Hospital Montefiore, Bronx, NY
Background/Purpose: Knowledge of co-occurring disease processes (comorbidities) is important for understanding disease pathogenesis, refining disease classifications, developing appropriate screening and prevention strategies, and determining overall…
Abstract Number: L2 • 2014 ACR/ARHP Annual Meeting
A Comparison of Three Treatment Strategies in Recent Onset DMARD Naïve Juvenile Idiopathic Arthritis: 3-Months Results of the BeSt for Kids-Study
Petra C.E. Hissink Muller^1,2, D.M.C. Brinkman^1,3, Dieneke Schonenberg⁴, Yvonne Koopman-Keemink⁵, J. Merlijn Van den Berg⁶, W.P. Bekkering⁷, Marion van Rossum^8,9, Lisette WA van Suijlekom-Smit¹⁰, Cornelia F. Allaart¹¹ and Rebecca ten Cate¹, ¹Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Pediatric Rheumatology, Reade, Amsterdam, Netherlands, ³Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, ⁴Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁵Pediatrics, Haga ziekenhuis, The Hague, Netherlands, ⁶Pediatric Hematology, Immunology and Infectious diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁷Pediatric Physiotherapy, Leiden University Medical Center, Leiden, Netherlands, ⁸Pediatric Rheumatology Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, ⁹Reade, Amsterdam, Netherlands, ¹⁰Pediatric Rheumatology, Sophia Children's Hospital Erasmus Medical Center, Rotterdam, Netherlands, ¹¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: BeSt for Kids compares 3 Disease Modifying Anti Rheumatic Drug (DMARD) strategies in juvenile idiopathic arthritis (JIA) patients, for time to inactive disease, time…
Abstract Number: 928 • 2014 ACR/ARHP Annual Meeting
A Multinational Study of the Epidemiology, Treatment and Outcome of Childhood Arthritis: Preliminary Data from 6,940 Patients
Alessandro Consolaro¹, Amita Aggarwal², Troels Herlin³, Olga Vougiouka⁴, Rubén Burgos-Vargas⁵, Ilonka Orban⁶, Nahid Shafaie⁷, Maria Trachana⁸, Lidia Rutkowska-Sak⁹, Ingrida Rumba-Rozenfelde¹⁰, Dimitrina Mihaylova¹¹, Alberto Martini^12,13 and Angelo Ravelli^1,14, ¹Pediatria II, Istituto Giannina Gaslini, Genova, Italy, ²Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ³Pediatric Rheumatology Clinic, Department of Pediatrics, Aarhus University Hospital, Aarhus, Denmark, ⁴P. A. Kyriakou Childrens Hospital of Athens University, Athens, Greece, ⁵Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ⁶National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, ⁷Rheumatology Research Centre, Tehran University of Medical Sciences, Tehran, Iran, ⁸Aristotle University, Thessaloniki, Greece, ⁹Institute of Rheumatology, Warsaw, Poland, ¹⁰University of Latvia, Riga, Latvia, ¹¹University Children Hospital, Sofia, Bulgaria, ¹²Istituto Giannina Gaslini, Genova, Italy, ¹³University of Genova, Genova, Italy, ¹⁴Istituto Giannina Gaslini and University of Genova, Genova, Italy
Background/Purpose The epidemiology of juvenile idiopathic arthritis (JIA) is known to be variable worldwide and the therapeutic approach to JIA is not standardized. Moreover, the…
Abstract Number: 303 • 2014 ACR/ARHP Annual Meeting
Predicting Chronic Pain in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Prospective Study
Amir Rashid¹, Kate Holliday¹, Lis Cordingley¹, Roberto Carrasco¹, Bo Fu², Helen E. Foster³, Eileen Baildam⁴, Alice Chieng⁵, Joyce Davidson⁶, Lucy Wedderburn⁷, Kimme Hyrich⁸ and Wendy Thomson⁹, ¹Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, ²Centre for Biostatistics, Institute of Population Health, The University of Manchester, Manchester, United Kingdom, ³Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ⁴Paediatric Rheumatology, Alder Hey Children's Foundation NHS Trust, Liverpool, United Kingdom, ⁵Paediatric Rheumatology, Royal Manchester Children's Hospital, Manchester, United Kingdom, ⁶Royal Hospital for Sick Children, Glasgow, United Kingdom, ⁷Rheumatology Unit , Institute of Child Health, University College London (UCL), London, United Kingdom, ⁸Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, ⁹Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom
· Background/Purpose: Pain is the most common symptom of JIA and has been associated with disease activity. However, disease activity has only accounted for a…
Abstract Number: 302 • 2014 ACR/ARHP Annual Meeting
Qualitative Assessment of Important Long-Term Outcomes in Juvenile Idiopathic Arthritis
Melissa L. Mannion¹, Michelle Williams², Gerald McGwin Jr.³, Kenneth G. Saag⁴ and Timothy Beukelman¹, ¹Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²School of Public Health, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL
Background/Purpose JIA is not a childhood disease, but a chronic disease that begins in childhood. Long term outcomes that physicians and patients care most about…
Abstract Number: 301 • 2014 ACR/ARHP Annual Meeting
Pregnancies in Females with Juvenile Idiopathic Arthritis (JIA) Who Were Exposed to Biologics and/or Methotrexate – Results from a Biologic Register
Katrin Stüdemann¹, Martina Niewerth¹, Jens Klotsche¹, Angela Zink², Gerd Horneff³ and Kirsten Minden^1,4, ¹Epidemiology unit, German Rheumatism Research Center, Berlin, Germany, ²German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, ³Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴Chidlrens´ hospital, Charité University Medicine, Berlin, Germany
Background/Purpose JIA often continues into adult life and affects about 1 in 1,000 people of childbearing age. Little is known about the impact of JIA…
Abstract Number: 288 • 2014 ACR/ARHP Annual Meeting
Establishing Clinical Meaning and Defining Important Differences in Patient Reported Outcome Measures of Physical Function, Fatigue and Pain Interference in Juvenile Idiopathic Arthritis
Esi M. Morgan DeWitt¹, Bin Huang^2,3, Kimberly Barnett⁴, Adam Carle⁵, Constance Mara⁶ and Karon Cook⁷, ¹Department of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH, ³Pediatrics, University of Cincinnati School of Medicine, Cincinnati, OH, ⁴Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶James M. Anderson Center for Health Systems Excellence, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁷Center for Patient-Centered Outcomes - Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
Background/Purpose Patient reported outcome measures (PROs) are used increasingly in clinical care. A framework to interpret scores according to degree of clinical severity would enhance…
Abstract Number: 279 • 2014 ACR/ARHP Annual Meeting
Focus on Patient Reported Outcomes in Juvenile Idiopathic Arthritis: There Is Room to Improve Care
Alysha Taxter¹, Keshia Maughn², Edward M. Behrens³ and Pamela F. Weiss⁴, ¹Pediatric Rheumatology, Children's Hospital of Philadelphia, Philadelphia, PA, ²Children's Hospital of Philadelphia, Philadelphia, PA, ³Pediatric Rheumatology, Childrens Hospital of Philadelphia, Philadelphia, PA, ⁴Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose National registry cross-sectional data show significant differences in patient-reported outcomes (PROs) across juvenile idiopathic arthritis (JIA) subtypes. This study aimed to assess predictors of…
Abstract Number: 2904 • 2014 ACR/ARHP Annual Meeting
Clinical and Radiological Features of Down’s Arthropathy
Charlene Foley, Orla Killeen and Emma Jane MacDermott, The National Centre for Paediatric Rheumatology, Dublin, Ireland
Background/Purpose The ‘Arthropathy of Down syndrome’ was first described in 1984. Three decades on we still have limited literature on the clinical & radiological features…
Abstract Number: 294 • 2014 ACR/ARHP Annual Meeting
Long-Term Pharmacokinetics of Body Surface Area-Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis
Jocelyn H. Leu¹, Alan M. Mendelsohn², Joyce Ford¹, Hugh M. Davis¹, Honghui Zhou¹ and Zhenhua Xu¹, ¹Janssen Research & Development, LLC., Spring House, PA, ²Immunology, Janssen Research & Development, LLC., Spring House, PA
Background/Purpose: To assess the pharmacokinetics (PK) and PK-efficacy correlations of body surface area (BSA)-adjusted dosing of 30 mg/m2 golimumab administered subcutaneously (SC) every 4 weeks…
Abstract Number: 2292 • 2014 ACR/ARHP Annual Meeting
Demographic, Clinical and Treatment Characteristics of the Childhood Arthritis and Rheumatology Research Alliance Registry Systemic JIA Cohort
Ginger L. Janow¹, Laura Schanberg², Soko Setoguchi³, Elizabeth D. Mellins⁴, Rayfel Schneider⁵, Yukiko Kimura^1,6 and The CARRA Registry Investigators⁷, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Duke University, Durham, NC, ³Duke Clinical Research Institute, Durham, NC, ⁴Dept of Pediatrics CCSR, Stanford University Medical Center, Stanford, CA, ⁵Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁶Pediatric Rheumatology, Hackensack Univ Medical Ctr, Hackensack, NJ, ⁷Childhood Arthritis and Rheumatology Research Alliance, Durham, NC
Background/Purpose: Systemic JIA (sJIA) is a rare disease whose treatment has changed in the past 10 yrs. The Childhood Arthritis and Rheumatology Research Alliance (CARRA)…
Abstract Number: 293 • 2014 ACR/ARHP Annual Meeting
Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register
Janneke Anink¹, Femke Prince¹, Maryanne Dijkstra¹, Marieke H. Otten¹, Marinka Twilt², Rebecca ten Cate³, Simone Gorter⁴, Yvonne Koopman-Keemink⁵, Marion A.J. Van Rossum^6,7, Esther P.A. Hoppenreijs^8,9 and Lisette W.A. van Suijlekom-Smit¹, ¹Pediatric Rheumatology, Erasmus MC Sophia Children's Hospital, Rotterdam, Netherlands, ²Pediatric Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ³Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁴Department of Internal Medicine, division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁵Pediatric Rheumatology, Hagaziekenhuis Juliana Children's Hospital, The Hague, Netherlands, ⁶Pediatric Rheumatology, Reade, location Jan van Breemen, Amsterdam, Netherlands, ⁷Pediatric Rheumatology, Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, ⁸Pediatric Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁹Pediatric Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands
Background/Purpose: Juvenile idiopathic arthritis patients refractory to methotrexate are eligible for treatment with biologic agents. A longitudinal sub-analysis (n=53) of the Dutch Arthritis and Biologicals…
Abstract Number: 2293 • 2014 ACR/ARHP Annual Meeting
Preliminary Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study
Yukiko Kimura¹, Esi Morgan-DeWitt², Kelly L. Mieszkalski³, Thomas Brent Graham⁴, Timothy Beukelman⁵, Maria F. Ibarra⁶, Norman T. Ilowite⁷, Marisa S. Klein-Gitelman⁸, Karen Onel⁹, Sampath Prahalad¹⁰, Marilynn G. Punaro¹¹, Sarah Ringold¹², Dana Toib¹³, Heather Van Mater¹⁴, Pamela F. Weiss¹⁵ and Laura Schanberg¹⁶, ¹Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Dept of Pediatrics, Duke University Medical Center, Durham, NC, ⁴Pediatric Rheumatology, Vanderbilt Children's Hospital, Nashville, TN, ⁵Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ⁷Pediatrics, Albert Einstein College of Medicine, Bronx, NY, ⁸Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁹Division of Pediatric Rheumatology, University of Chicago, Chicago, IL, ¹⁰Emory University School of Medicine, Atlanta, GA, ¹¹Pediatrics, University of Texas Southwestern Medical Center, Dallas, TX, ¹²Seattle Children's Hospital, Seattle, WA, ¹³St. Christopher's Hospital for Children, Philadelphia, PA, ¹⁴Duke Pediatric Rheumatology, Duke University Medical Center, Hillsborough, NC, ¹⁵Rheumatology, The Children's Hospital of Philadelphia, Philadelphia, PA, ¹⁶Duke University, Durham, NC
Background/Purpose: Treatment options for systemic JIA (sJIA) have recently expanded to include IL1 and IL6 inhibitors in addition to traditional treatments such as glucocorticoids (GC)…
Abstract Number: 290 • 2014 ACR/ARHP Annual Meeting
Patterns of Active Joint Involvement in JIA
Simon W.M. Eng¹, Mira Van Veenendaal², Alan M. Rosenberg³, Kiem Oen⁴, Quaid Morris¹ and Rae S.M. Yeung², ¹University of Toronto, Toronto, ON, Canada, ²Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ³Department of Pediatrics, University of Saskatchewan, Saskatoon, SK, Canada, ⁴Pediatrics RR149 Rehab Ctr, University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: JIA encompasses a set of heterogeneous diseases with chronic joint inflammation. Although the ILAR criteria consider joint counts, they do not reflect specific joint…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].